Elbasvir and grazoprevir for the treatment of hepatitis C

被引：3

作者：

Wang, Szu-Jen ^{[1
,2
]}

Huang, Chung-Feng ^{[3
,4
]}

Yu, Ming-Lung ^{[1
,3
,4
]}

机构：

[1] Kaohsiung Med Univ, Grad Inst Clin Med, Kaohsiung, Taiwan

[2] Yuans Gen Hosp, Dept Internal Med, Div Gastroenterol, Kaohsiung, Taiwan

[3] Kaohsiung Med Univ Hosp, Dept Internal Med, Hepatobiliary Div, Kaohsiung 807, Taiwan

[4] Kaohsiung Med Univ, Coll Med, Fac Internal Med, Kaohsiung, Taiwan

来源：

EXPERT REVIEW OF ANTI-INFECTIVE THERAPY | 2021年 / 19卷 / 09期

关键词：

Direct-acting antivirals; elbasvir; grazoprevir; hepatitis C virus; genotype; 1; or; 4; sustained viral response; efficacy; safety; tolerability; drug-drug interaction; VIRUS GENOTYPE 1; HCV NS5A INHIBITOR; INFECTION; ELBASVIR/GRAZOPREVIR; ASSOCIATION; EFFICACY; MK-8742; SAFETY; TRANSPLANTATION; COINFECTION;

D O I：

10.1080/14787210.2021.1874351

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Introduction: Hepatitis C is one of the leading causes of chronic liver disease. The direct-acting-antivirals has revolutionized the chronic hepatitis C treatment. DAAs can achieve a sustained virological response rate >95% in different populations. Area covered: This review summarizes the pharmacokinetics, pharmacodynamics, efficacy, and safety of Elbasvir/Grazoprevir (EBR/GZR). Expert opinion: EBR/GZR is a combination of NS5A and NS3/4A inhibitors. The performance in the EBR/GZR combination's safety and tolerability is appreciated in clinical treatment. EBR/GZR also has a higher barrier to resistance-associated substitutions. Based on clinical trials and real-world experience, elbasvir/grazoprevir is effective in the HCV GT1, 4 infections.

引用

页码：1071 / 1081

页数：11

共 50 条

[31] Elbasvir/Grazoprevir in Black Adults With Hepatitis C Virus Infection: A Pooled Analysis of Phase 2/3 Clinical Trials [J].

Zamor, Philippe J. ;

Vierling, John ;

Ghalib, Reem ;

Luketic, Velimir ;

Ravendhran, Natarajan ;

Balart, Luis ;

Robertson, Michael ;

Hwang, Peggy ;

Hanna, George J. ;

Nguyen, Bach-Yen ;

Barr, Eliav ;

Talwani, Rohit ;

Pearlman, Brian .

AMERICAN JOURNAL OF GASTROENTEROLOGY, 2018, 113 (06) :863-871

[32] Cost-Effectiveness of Testing for NS5A Resistance to Optimize Treatment of Elbasvir/Grazoprevir for Chronic Hepatitis C in China [J].

Liu, Jinyu ;

Zhang, Yu ;

Wu, Bin ;

Wang, Sen ;

Bin-Chia Wu, David ;

You, Ruxu .

FRONTIERS IN PHARMACOLOGY, 2021, 12

[33] A Phase I, Single- and Multiple-dose Study to Evaluate the Pharmacokinetics of Elbasvir and Grazoprevir in Healthy Chinese Participants [J].

Cheung, Tommy Tsang ;

Chiu, Joanne Wing Yan ;

Yuen, Man Fung ;

Lam, Karen Siu Ling ;

Cheung, Bernard Man Yung ;

Feng, Hwa-Ping ;

Yeh, Wendy W. ;

Wang, Jiangdian ;

Li, Wenting ;

Zhao, Xu Min ;

Wang, Zaiqi ;

Mu, Shengmei .

CLINICAL THERAPEUTICS, 2018, 40 (05) :719-732

[34] Elbasvir/Grazoprevir (Zepatier) for Hepatitis C Virus Infection [J].

Early, Jessica ;

Maxted, George .

AMERICAN FAMILY PHYSICIAN, 2017, 95 (06) :393-394

[35] No Pharmacokinetic Interaction Between the Hepatitis C Virus Inhibitors Elbasvir/Grazoprevir and Famotidine or Pantoprazole [J].

Feng, H-P ;

Vaddady, P. ;

Guo, Z. ;

Liu, F. ;

Panebianco, D. ;

Levine, V. ;

Caro, L. ;

Butterton, J. R. ;

Iwamoto, M. ;

Yeh, W. W. .

CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2017, 10 (05) :360-365

[36] Effect of Hepatic Impairment on the Pharmacokinetics of Grazoprevir, a Hepatitis C Virus Protease Inhibitor [J].

Caro, Luzelena ;

Wenning, Larissa ;

Guo, Zifang ;

Fraser, Iain P. ;

Fandozzi, Christine ;

Talaty, Jennifer ;

Panebianco, Deborah ;

Ho, Maureen ;

Uemura, Naoto ;

Reitmann, Christina ;

Angus, Peter ;

Gane, Edward ;

Marbury, Thomas ;

Smith, William B. ;

Iwamoto, Marian ;

Butterton, Joan R. ;

Yeh, Wendy W. .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2017, 61 (12)

[37] Effectiveness of elbasvir/grazoprevir plus ribavirin for hepatitis C virus genotype 1a infection and baseline NS5A resistance [J].

Hill, Deanna D. ;

Kramer, Jennifer R. ;

Chaffin, Kassie R. ;

Mast, T. Christopher ;

Robertson, Michael N. ;

Kanwal, Fasiha ;

Haber, Barbara A. .

ANNALS OF HEPATOLOGY, 2023, 28 (02)

[38] Real-world virological efficacy and safety of elbasvir and grazoprevir in patients with chronic hepatitis C virus genotype 1 infection in Japan [J].

Hidenori Toyoda ;

Masanori Atsukawa ;

Koichi Takaguchi ;

Tomonori Senoh ;

Kojiro Michitaka ;

Atsushi Hiraoka ;

Shinichi Fujioka ;

Chisa Kondo ;

Tomomi Okubo ;

Haruki Uojima ;

Toshifumi Tada ;

Hirohito Yoneyama ;

Tsunamasa Watanabe ;

Toru Asano ;

Toru Ishikawa ;

Hideyuki Tamai ;

Hiroshi Abe ;

Keizo Kato ;

Kunihiko Tsuji ;

Chikara Ogawa ;

Noritomo Shimada ;

Etsuko Iio ;

Akihiro Deguchi ;

Ei Itobayashi ;

Shigeru Mikami ;

Akio Moriya ;

Hironao Okubo ;

Joji Tani ;

Akihito Tsubota ;

Yasuhito Tanaka ;

Tsutomu Masaki ;

Katsuhiko Iwakiri ;

Takashi Kumada .

Journal of Gastroenterology, 2018, 53 :1276-1284

[39] Spotlight on grazoprevir-elbasvir once-daily combination and its potential in the treatment of hepatitis C [J].

Suraweera, Duminda ;

Weeratunga, Ashley N. ;

Saab, Sammy .

DRUG DESIGN DEVELOPMENT AND THERAPY, 2016, 10 :2119-2127

[40] Short-Duration Treatment With Elbasvir/Grazoprevir and Sofosbuvir for Hepatitis C: A Randomized Trial [J].

Lawitz, Eric ;

Poordad, Fred ;

Gutierrez, Julio A. ;

Wells, Jennifer T. ;

Landaverde, Carmen E. ;

Evans, Barbara ;

Howe, Anita ;

Huang, Hsueh-Cheng ;

Li, Jerry Jing ;

Hwang, Peggy ;

Dutko, Frank J. ;

Robertson, Michael ;

Wahl, Janice ;

Barr, Eliav ;

Haber, Barbara .

HEPATOLOGY, 2017, 65 (02) :439-450

← 1 2 3 4 5 →